Antibiotic prophylaxis with contrimoxazole/colistin similar to ciprofloxacin in acute myeloid leukemia
the ONA take:
Recent meta-analyses showed that incidence of fever and mortality rate were reduced in patients with neutropenia after chemotherapy when antibiotic prophylaxis was administered.
As fluoroquinolones appear to be most effective and well tolerated, a German team changed the antibiotic prophylaxis regimen used from cotrimoxazole/colistin (COT/COL) to ciprofloxacin (CIP) in patients with acute myeloid leukemia (AML).
In this retrospective study, they compare the efficacy and development of bacterial resistance with the two prophylaxis regimens over a period of more than 4 years via a standard questionnaire.
The findings show no significant difference in incidence of fever between the COT/COL group and the CIP group.
In addition, the rates of both microbiologically and clinically documented infections were similar, as well as rates of gram-positive and gram-negative bacteria.
No increases in resistance rates or cases with Clostridium difficile-associated diarrhea in the CIP group were noted.
The researchers conclude antibiotic prophylaxis with CIP and COT/COL in patients with AML was similarly effective with no increase in bacterial resistance.
Antibiotic prophylaxis regimen used from cotrimoxazole/colistin (COT/COL) to ciprofloxacin (CIP) in patients with AML.
Sign Up for Free e-newsletters
- Incidence of Post-traumatic Stress Disorder High Among Patients With Cancer
- Long-Term Night Shift Work Associated With Cancer Risk in Women
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Breast Cancer Deaths Decrease Sharply Since 2000
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|